Coherus Oncology
CHRS
114 hedge funds and large institutions have $84.6M invested in Coherus Oncology in 2025 Q3 according to their latest regulatory filings, with 21 funds opening new positions, 37 increasing their positions, 30 reducing their positions, and 17 closing their positions.
302% more call options, than puts
Call options by funds: $920K | Put options by funds: $229K
109% more capital invested
Capital invested by funds: $40.4M → $84.6M (+$44.2M)
24% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 17
23% more repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 30
18.81% more ownership
Funds ownership: 47.7% → 66.51% (+19%)
2% more funds holding
Funds holding: 112 → 114 (+2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
+$647K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$246K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$219K |
| 4 |
Jane Street
New York
|
+$163K |
| 5 |
AQR Capital Management
Greenwich,
Connecticut
|
+$149K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$1.01M |
| 2 |
Citigroup
New York
|
-$821K |
| 3 |
RCMNY
Rubric Capital Management (New York)
New York
|
-$635K |
| 4 |
Renaissance Technologies
New York
|
-$555K |
| 5 |
TC
Tejara Capital
London,
United Kingdom
|
-$511K |
CHRS Hedge Fund Activity: Q3 2025 in Review
114 of the 7,640 institutional investors tracked by Wall St. Rank reported a position in Coherus Oncology (CHRS) for Q3 2025, worth a combined $84.6M — up 109% from $40.4M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new CHRS positions and 17 closed out — a net gain of 4 holders — while 37 added to existing stakes and 30 trimmed.
The largest buyer was Panagora Asset Management, adding an estimated $647K. The largest seller was Millennium Management, exiting entirely with an estimated $1.01M sold.
- 114 institutional investors held Coherus Oncology (CHRS) as of Q3 2025, up from 112 in Q2 2025.
- Funds reported $84.6M of Coherus Oncology stock for Q3 2025, up 109% quarter-over-quarter.
- 21 funds opened new Coherus Oncology positions in Q3 2025 and 17 closed out, a net change of +4 holders.
- The largest Coherus Oncology buyer in Q3 2025 was Panagora Asset Management, an estimated $647K added.
- The largest Coherus Oncology seller in Q3 2025 was Millennium Management, an estimated $1.01M sold.
Based on aggregated 13F filings for Q3 2025.